Abstract: Provided are lipid particles encapsulating a nucleic acid capable of expressing an E6 antigen and an E7 antigen of human papillomavirus, whereby a vaccine for preventing and/or treating infection with human papillomavirus type 6 and/or type 11 can be provided. The lipid particles comprise a lipid that is a cationic lipid having the general formula (Ia), or a pharmaceutically acceptable salt thereof. [In the formula, R1, R2, p, L1 and L2 are as defined in the specification.

Abstract: Provided are lipid particles encapsulating a nucleic acid capable of expressing an E6 antigen and an E7 antigen of human papillomavirus, whereby a vaccine for preventing and/or treating infection with human papillomavirus type 6 and/or type 11 can be provided. The lipid particles comprise a lipid that is a cationic lipid having the general formula (Ia), or a pharmaceutically acceptable salt thereof. [In the formula, R1, R2, p, L1 and L2 are as defined in the specification.

Abstract: Provided is a vaccine for preventing and/or treating an infection with an influenza virus. The vaccine comprises lipid particles containing a nucleic acid capable of expressing a haemagglutinin (HA) protein of the influenza virus, wherein a lipid is a cationic lipid having general formula (Ia), or a pharmaceutically acceptable salt thereof. [In the formula, R1, R2, p, L1 and L2 are as defined in the specification.

Abstract: Provided is a vaccine for preventing and/or treating infection with human T-cell leukemia virus type 1 (HTLV-1). A lipid particle encapsulating a nucleic acid expressing a gp46 antigen or a Tax antigen of human T-cell leukemia virus type 1 (HTLV-1), wherein the lipid comprises a cationic lipid represented by general formula (Ia): or a pharmaceutically acceptable salt thereof, wherein R1 and R2 each independently represent a C1-C3 alkyl group; L1 represents a C17-C19 alkenyl group optionally having one or more C2-C4 alkanoyloxy groups; L2 represents a C10-C19 alkyl group optionally having one or more C2-C4 alkanoyloxy groups, or a C10-C19 alkenyl group optionally having one or more C2-C4 alkanoyloxy groups; and p is 3 or 4.

Abstract: The present invention provides a vaccine for preventing and/or treating infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The present invention relates to a lipid particle encapsulating a nucleic acid molecule capable of expressing the S protein and/or a fragment thereof of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), wherein the lipid comprises a cationic lipid represented by general formula (Ia) or a pharmaceutically acceptable salt thereof: wherein R1 and R2 each independently represent a C1-C3 alkyl group; L1 represents a C17-C19 alkenyl group which may have one or a plurality of C2-C4 alkanoyloxy groups; L2 represents a C10-C19 alkyl group which may have one or a plurality of C2-C4 alkanoyloxy groups or a C10-C19 alkenyl group which may have one or a plurality of C2-C4 alkanoyloxy groups; and p is 3 or 4.

Abstract: The present invention provides a vaccine for preventing and/or treating infections with human papillomavirus. The present invention relates to a lipid particle encapsulating a nucleic acid molecule capable of expressing the E6 and E7 antigens of human papillomavirus, wherein the lipid comprises a cationic lipid represented by general formula (Ia) or a pharmaceutically acceptable salt thereof: wherein R1 and R2 each independently represent a C1-C3 alkyl group; L1 represents a C17-C19 alkenyl group which may have one or a plurality of C2-C4 alkanoyloxy groups; L2 represents a C10-C19 alkyl group which may have one or a plurality of C2-C4 alkanoyloxy groups or a C10-C19 alkenyl group which may have one or a plurality of C2-C4 alkanoyloxy groups; and p is 3 or 4.

Abstract: The present invention provides an oligodeoxynucleotide containing humanized K type CpG oligodeoxynucleotide and poly deoxyadenylate, wherein the poly deoxyadenylate is placed on the 3?-side of the humanized K type CpG oligodeoxynucleotide. In addition, the present invention provides a complex containing the aforementioned oligodeoxynucleotide and ?-1,3-glucan.

Abstract: The present invention provides a compound represented by the formula (Ia) as a novel cationic lipid that forms a lipid particle and also provides a lipid particle comprising the compound. The present invention further provides a nucleic acid lipid particle containing the lipid particle, and a pharmaceutical composition containing the nucleic acid lipid particle as an active ingredient.

Abstract: The present invention provides a compound represented by the formula (Ia) as a novel cationic lipid that forms a lipid particle and also provides a lipid particle comprising the compound. The present invention further provides a nucleic acid lipid particle containing the lipid particle, and a pharmaceutical composition containing the nucleic acid lipid particle as an active ingredient.

Abstract: The present invention provides a compound represented by the formula (Ia) as a novel cationic lipid that forms a lipid particle and also provides a lipid particle comprising the compound. The present invention further provides a nucleic acid lipid particle containing the lipid particle, and a pharmaceutical composition containing the nucleic acid lipid particle as an active ingredient.

Abstract: The present invention provides an oligodeoxynucleotide containing humanized K type CpG oligodeoxynucleotide and poly deoxyadenylate, wherein the poly deoxyadenylate is placed on the 3?-side of the humanized K type CpG oligodeoxynucleotide. In addition, the present invention provides a complex containing the aforementioned oligodeoxynucleotide and ?-1,3-glucan.

Abstract: The present invention provides an oligodeoxynucleotide containing humanized K type CpG oligodeoxynucleotide and poly deoxyadenylate, wherein the poly deoxyadenylate is placed on the 3?-side of the humanized K type CpG oligodeoxynucleotide. In addition, the present invention provides a complex containing the aforementioned oligodeoxynucleotide and ?-1,3-glucan.

Abstract: The present invention provides a compound represented by the formula (Ia) as a novel cationic lipid that forms a lipid particle and also provides a lipid particle comprising the compound. The present invention further provides a nucleic acid lipid particle containing the lipid particle, and a pharmaceutical composition containing the nucleic acid lipid particle as an active ingredient.

Abstract: The present invention provides a compound represented by the formula (Ia) as a novel cationic lipid that forms a lipid particle and also provides a lipid particle comprising the compound. The present invention further provides a nucleic acid lipid particle containing the lipid particle, and a pharmaceutical composition containing the nucleic acid lipid particle as an active ingredient.

Abstract: The present invention provides a compound represented by the formula (Ia) as a novel cationic lipid that forms a lipid particle and also provides a lipid particle comprising the compound. The present invention further provides a nucleic acid lipid particle containing the lipid particle, and a pharmaceutical composition containing the nucleic acid lipid particle as an active ingredient.

Abstract: The present invention provides an oligodeoxynucleotide containing humanized K type CpG oligodeoxynucleotide and poly deoxyadenylate, wherein the poly deoxyadenylate is placed on the 3?-side of the humanized K type CpG oligodeoxynucleotide. In addition, the present invention provides a complex containing the aforementioned oligodeoxynucleotide and ?-1,3-glucan.

Abstract: Disclosed herein is a stent delivery system which includes: a hollow shaft; first and second expandable balloons arranged around of the distal end of the shaft; and a stent which is arranged around the second balloon such that it expands as the second balloon expands; the first balloon having drug release means for releasing a drug at least to prevent the proliferation of endothelial cells, the stent being a bare metal stent to be indwelled at a target position as lesion of stenosis or occlusion in the lumen of a living body.

Abstract: Disclosed herein is a stent delivery system which includes: a hollow shaft; first and second expandable balloons arranged around of the distal end of the shaft; and a stent which is arranged around the second balloon such that it expands as the second balloon expands; the first balloon having drug release means for releasing a drug at least to prevent the proliferation of endothelial cells, the stent being a bare metal stent to be indwelled at a target position as lesion of stenosis or occlusion in the lumen of a living body.

Abstract: Disclosed herein is a stent delivery system which includes: a hollow shaft; first and second expandable balloons arranged around of the distal end of the shaft; and a stent which is arranged around the second balloon such that it expands as the second balloon expands; the first balloon having drug release means for releasing a drug at least to prevent the proliferation of endothelial cells, the stent being a bare metal stent to be indwelled at a target position as lesion of stenosis or occlusion in the lumen of a living body.

Abstract: The present invention relates to an immunoliposome preparation or a hydrophobic molecule-modified antibody having a therapeutic effect on cancer, autoimmune disease, or inflammatory disease. Specifically, the present invention relates to an immunoliposome or a hydrophobic molecule-modified antibody comprising, as a constituent, an antibody capable of inducing the apoptosis of cells expressing a death domain-containing receptor.